Administration Options

INTELENCE® (etravirine) Dosing and Administration

Recommended Dosage in Adult Patients
The recommended oral dosage of INTELENCE® for adult patients is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. The type of food does not affect the exposure to INTELENCE®.

Recommended Dosage During Pregnancy
The recommended oral dosage of INTELENCE® for pregnant individuals is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal.

Recommended Dosage in Pediatric Patients (2 Years to Less Than 18 Years of Age)
The recommended dosage of INTELENCE® for pediatric patients 2 years to less than 18 years of age and weighing at least 10 kg is based on body weight (see Table 1 in the Prescribing Information) not exceeding the recommended adult dosage. INTELENCE® should be taken orally, following a meal. The type of food does not affect the exposure to INTELENCE®.

2 Tablets Twice Daily

INTELENCE® may be dispersed in water for patients unable to swallow tablets whole

If you are unable to swallow INTELENCE® tablets whole, you may take your dose of INTELENCE® as follows:

Step 1: Measure approximately 5 mL (1 teaspoon) of water and pour into a cup.

Step 2: Place the tablets in the cup containing 5 mL of water. If needed, add more water to cover the tablets. Do not put the tablets in other liquids.

Step 3: Stir well until the water looks milky.

Step 4: Add a small amount (approximately 15 mL or 1 tablespoon) of liquid. Water may be used, but adding orange juice or milk rather than water may make it easier to take. Do not use warm (temperature more than 104°F or 40°C) or carbonated beverages.

Step 5: Drink the mixture right away.

Step 6: Add more orange juice, milk, or water to the cup to rinse the cup several times and completely swallow each time to make sure you take your entire dose of INTELENCE®.

No dose adjustments are necessary in…

  • Patients with mild or moderate hepatic impairment
    (Child-Pugh Class A or B)
    • The pharmacokinetics of INTELENCE® have not been evaluated in patients with severe hepatic impairment
      (Child-Pugh Class C)
  • Patients coinfected with hepatitis B and/or C virus
  • Patients with renal impairment

Please see full description of study design and baseline characteristics.


Important Safety Information